Antiviral drug

Anti-Viral Therapies Market to Reach $46.21 Bn, Globally, by 2026 at 2.4% CAGR: Allied Market Research

Tuesday, June 2, 2020 - 3:20pm

"According to the report, the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.

Key Points: 
  • "According to the report, the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.
  • Increase in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market.
  • The coronavirus outbreak has not much affected the global anti-viral therapies market.
  • In addition, the anti-viral therapies also include essential treatments on HIV, hepatitis and herpes, which drive the demand in the market.

Anti-Viral Therapies Market to Reach $46.21 Bn, Globally, by 2026 at 2.4% CAGR: Allied Market Research

Tuesday, June 2, 2020 - 3:20pm

"According to the report, the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.

Key Points: 
  • "According to the report, the global anti-viral therapies market garnered $38.31 billion in 2018, and is estimated to reach $46.21 billion by 2026, registering a CAGR of 2.4% from 2019 to 2026.
  • Increase in problem of viral infection and stronger pipeline of anti-viral drugs across the globe drive the growth of the global anti-viral therapies market.
  • The coronavirus outbreak has not much affected the global anti-viral therapies market.
  • In addition, the anti-viral therapies also include essential treatments on HIV, hepatitis and herpes, which drive the demand in the market.

RDIF and ChemRar to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia, Avifavir, to the Country's Hospitals in June

Monday, June 1, 2020 - 7:30am

Avifavir is Russia's first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.

Key Points: 
  • Avifavir is Russia's first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
  • Deliveries of the first batches of the drug to Russian hospitals are expected on June 11, 2020.
  • Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct-acting antiviral drug that has proven effective in clinical trials.
  • The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.

RDIF and ChemRar to Deliver 60,000 Courses of the First COVID-19 Drug Registered in Russia, Avifavir, to the Country's Hospitals in June

Monday, June 1, 2020 - 7:30am

Avifavir is Russia's first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.

Key Points: 
  • Avifavir is Russia's first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
  • Deliveries of the first batches of the drug to Russian hospitals are expected on June 11, 2020.
  • Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct-acting antiviral drug that has proven effective in clinical trials.
  • The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time

Monday, June 1, 2020 - 2:00am

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

Key Points: 
  • Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.
  • The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment.
  • This announcement follows the identification of antibody candidates for an antiviral treatment which Celltrion completed in April.
  • In response to these positive results, Celltrion will now conduct additional efficacy and toxicity testing in pre-clinical settings and anticipates starting first-in-human clinical trials in July.

SwRI Awarded $1.9 Million Contract to Develop Treatment for COVID-19 in Collaboration with DOD

Thursday, May 28, 2020 - 3:00pm

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF) has awarded SwRI a $1.9 million, one-year contract to support these efforts to identify potential COVID-19 treatments.

Key Points: 
  • The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF) has awarded SwRI a $1.9 million, one-year contract to support these efforts to identify potential COVID-19 treatments.
  • SwRI is working with the DOD High Performance Computing Modernization Program to rapidly screen potential drug compounds using SwRIs 3D drug screening software tool, Rhodium.
  • This grant will enable SwRI to collaborate to develop safe antiviral drug therapy treatment options for COVID in record time, said Dr. Joe McDonough, director of SwRIs Pharmaceutical and Bioengineering Department.
  • The Institute has previously used this process to develop drug treatment therapies for Ebola virus, malaria and other infectious diseases.

resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents

Thursday, May 28, 2020 - 12:00pm

The study is supported by additional data observed in resTORbio Phase 2b and Phase 3 clinical trials which suggest the potential of RTB101 to reduce the severity of laboratory-confirmed coronavirus infections.

Key Points: 
  • The study is supported by additional data observed in resTORbio Phase 2b and Phase 3 clinical trials which suggest the potential of RTB101 to reduce the severity of laboratory-confirmed coronavirus infections.
  • As previously disclosed, resTORbio has conducted two double-blind, randomized, placebo-controlled trials of RTB101 for prevention of respiratory tract infections (RTIs) in adults aged 65 years.
  • Treatment with RTB101 10mg once daily is associated with a numerical decrease in the incidence and severity of coronavirus infections as compared to placebo.
  • In previous Phase 2 studies, RTB101 was observed to upregulate innate antiviral gene expression, and therefore RTB101 has the potential to be a pan-antiviral immunotherapy.

Merck to Announce Multiple Scientific Efforts to Combat COVID-19

Tuesday, May 26, 2020 - 11:45am

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate.
  • With our singular legacy and expertise in vaccines and anti-infective medicines, we know Merck has a responsibility to engage in the scientific communitys efforts to find new medicines and vaccines to bring this pandemic to an end, said Kenneth C. Frazier, chairman and chief executive officer, Merck.
  • We will ensure that all of these programs have the resources, attention and focus they need and that the COVID-19 pandemic demands.
  • Though the challenge of this pandemic is immense, we know that science and collaboration will triumph, just as they have before.

Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:15am

However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.

Key Points: 
  • However, the market growth would be challenged by high cost involves in drug development, threats associated with drug counterfeiting and stringent government regulations.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.
  • The report provides a comprehensive analysis of the global antiviral drugs market.

Insights into the Worldwide Antiviral Drugs Industry to 2024 - Potential Impact of COVID-19 - ResearchAndMarkets.com

Friday, May 22, 2020 - 2:55pm

The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antiviral Drugs Market (By Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • The global antiviral drugs market is expected to reach US$ 70.95 billion in 2024, increasing at a CAGR of 2.10%, for the duration of 2020-2024.
  • The global antiviral drugs market is fragmented into branded drugs and generic drugs.
  • Branded drugs dominate the market owing to the increased levels of trust and reliability associated with branded pharmaceutical companies among customers.